Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer

NCT03382912 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
52
Enrollment
INDUSTRY
Sponsor class

Stopped The CYPRESS-2 trial was closed early after the planned final analysis because the risk benefit ratio is unfavorable.

Conditions

Interventions

Sponsor

Eli Lilly and Company

Collaborators